USA flag logo/image

An Official Website of the United States Government

Use of recombinant human lactoferrin for wounds by stimulating cell growth

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
79767
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
GM079025
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
VENTRIA BIOSCIENCE
320 East Vine Drive FORT COLLINS, CO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2006
Title: Use of recombinant human lactoferrin for wounds by stimulating cell growth
Agency: HHS
Contract: 1R43GM079025-01
Award Amount: $113,851.00
 

Abstract:

DESCRIPTION (provided by applicant): Acute and chronic wound care continues to pose major challenges in both civilian and military forces. It is estimated that 6 million people in the United States were affected by chronic wounds, such as venous ulcers. As of November 2005, 15,568 US soldiers in Operation Iraqi Freedom were wounded and about 50% of the injured were unable to return to duty within 72 hours of injury. Wounds, acute or chronic, not only threaten the life of the wounded, but also increase frailty in the elderly, decrease quality of life, and loss in productivity. The high costs associated with the management of slow-healing wounds have an enormous impact on the economy. In the US alone, $2.8 billion is spent annually to treat chronic wounds and the worldwide market reaches $7 billion. This problem can partially be alleviated by rapid wound healing. Currently, extensive efforts are being made to develop growth factors as wound healing agents; however, not all studies show the same results further growth factors do not provide any antimicrobial effects to prevent infection. Delayed cell growth and migration of keratinocytes and fibroblasts and microbial infections at the wound site impairs wound healing. We propose to use lactoferrin (LF) as a novel wound healing agent based on its ability to promote cell growth and its antimicrobial properties. To test the effectiveness of LF on wound healing, recombinant human LF (rhLF), produced in rice, will be purified and examined for its effects on the proliferation and migration of human epithelial keratinocyte and fibroblast in vitro. To study the effects of rhLF on cell migration, an incisional wound cell model will be used and the migration of cells will be observed. Data from these in vitro studies will provide the fundamental basis for future investigation of rhLF on wound healing in an animal model and in humans. In addition, purification procedures developed in Phase I will be implemented in scale- up processing of rhLF for Phase II. The long term goal of this project is to commercialize a new topical agent for rapid wound healing, which would in turn decrease the burden wounds have on the economy and society. The high costs associated with the management of wounds have an enormous impact on the economy. Administration of a novel topical wound healing agent, lactoferrin (LF) would promote cell growth/migration with added benefit of preventing/treating bacterial infections. The use of LF would 1) alleviate the burden wounds have on the economy and society and 2) benefit the elderly, diabetics, immunocompromised patients, and military forces injured in combat.

Principal Investigator:

Ning Huang
9169216148
NHUANG@VENTRIA.COM

Business Contact:


9169216148
Small Business Information at Submission:

VENTRIA BIOSCIENCE
VENTRIA BIOSCIENCE 4110 N FREEWAY BLVD SACRAMENTO, CA 95834

EIN/Tax ID: 680310843
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No